apn-1125
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02331433)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Neuronal acetylcholine receptor protein alpha-7 subunitPARTIAL AGONIST
CHRNA7 partial agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545013 ↗
Also known as
- apn1125
- apn1125
- apn-1125
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02724917 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Alpharmagen, Inc., Collaborative Neuroscience Network, CoMentis |
| NCT02331433 | Phase 1 | Dec 1, 2014 | Alpharmagen, Inc., California Clinical Trials, CoMentis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alpharmagen, Inc. | For profit | 2 | 0 | 2 | 2014 |
| CoMentis | For profit | 2 | 2 | 2 | 2014 |
| California Clinical Trials | For profit | 1 | 0 | 1 | 2014 |
| Collaborative Neuroscience Network | For profit | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1